User login
SAN ANTONIO – High levels of tumor-infiltrating lymphocytes in primary breast cancer are a good biomarker for favorable clinical response to trastuzumab, according to research presented at the San Antonio Breast Cancer Symposium.
In an exclusive interview with Frontline Medical News, Dr. Sherene Loi discusses the findings' clinical implications, including the potential that breast cancers could be amenable to immunotherapeutic approaches.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
SAN ANTONIO – High levels of tumor-infiltrating lymphocytes in primary breast cancer are a good biomarker for favorable clinical response to trastuzumab, according to research presented at the San Antonio Breast Cancer Symposium.
In an exclusive interview with Frontline Medical News, Dr. Sherene Loi discusses the findings' clinical implications, including the potential that breast cancers could be amenable to immunotherapeutic approaches.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
SAN ANTONIO – High levels of tumor-infiltrating lymphocytes in primary breast cancer are a good biomarker for favorable clinical response to trastuzumab, according to research presented at the San Antonio Breast Cancer Symposium.
In an exclusive interview with Frontline Medical News, Dr. Sherene Loi discusses the findings' clinical implications, including the potential that breast cancers could be amenable to immunotherapeutic approaches.
